Literature DB >> 10037103

Natural history of dysplasia of the uterine cervix.

P Holowaty1, A B Miller, T Rohan, T To.   

Abstract

BACKGROUND: A historical cohort of Toronto (Ontario, Canada) women whose Pap smear histories were recorded at a major cytopathology laboratory provided the opportunity to study progression and regression of cervical dysplasia in an era (1962-1980) during which cervical squamous lesions were managed conservatively.
METHODS: Actuarial and Cox's survival analyses were used to estimate the rates and relative risks of progression and regression of mild (cervical intraepithelial neoplasia 1 [CIN1]) and moderate (CIN2) dysplasias. In addition, more than 17,000 women with a history of Pap smears between 1970 and 1980 inclusive and who were diagnosed as having mild, moderate, or severe dysplasia were linked to the Ontario Cancer Registry for the outcome of any subsequent cervical cancers occurring through 1989.
RESULTS: Both mild and moderate dysplasias were more likely to regress than to progress. The risk of progression from mild to severe dysplasia or worse was only 1% per year, but the risk of progression from moderate dysplasia was 16% within 2 years and 25% within 5 years. Most of the excess risk of cervical cancer for severe and moderate dysplasias occurred within 2 years of the initial dysplastic smear. After 2 years, in comparison with mild dysplasia, the relative risks for progression from severe or moderate dysplasia to cervical cancer in situ or worse was 4.2 (95% confidence interval [CI] = 3.0-5.7) and 2.5 (95% CI = 2.2-3.0), respectively.
CONCLUSION: The risk of progression for moderate dysplasia was intermediate between the risks for mild and severe dysplasia; thus, the moderate category may represent a clinically useful distinction. The majority of untreated mild dysplasias were recorded as regressing to yield a normal smear within 2 years.

Entities:  

Mesh:

Year:  1999        PMID: 10037103     DOI: 10.1093/jnci/91.3.252

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  107 in total

1.  Cervical cytology: are national guidelines adequate for women attending genitourinary medicine clinics?

Authors:  E Foley; V Harindra
Journal:  Sex Transm Infect       Date:  1999-10       Impact factor: 3.519

2.  Cervical cancer in the developing world.

Authors:  J Sherris; C Herdman; C Elias
Journal:  West J Med       Date:  2001-10

Review 3.  How can we develop a cost-effective quality cervical screening programme?

Authors:  Sue Wilson; Helen Lester
Journal:  Br J Gen Pract       Date:  2002-06       Impact factor: 5.386

4.  Perspectives on personalized cancer care.

Authors:  Garrett M Dancika; Dan Theodorescu
Journal:  Urol Oncol       Date:  2012 Mar-Apr       Impact factor: 3.498

5.  Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: a prospective cohort.

Authors:  Tanvier Omar; Sheree Schwartz; Colleen Hanrahan; Tebogo Modisenyane; Nkeko Tshabangu; Jonathan E Golub; James A McIntyre; Glenda E Gray; Lerato Mohapi; Neil A Martinson
Journal:  AIDS       Date:  2011-01-02       Impact factor: 4.177

6.  Matching intra-procedural information with coping style reduces psychophysiological arousal in women undergoing colposcopy.

Authors:  Susanna Kola; Jane C Walsh; Brian M Hughes; Siobhán Howard
Journal:  J Behav Med       Date:  2012-06-24

Review 7.  Design of cancer screening trials/randomized trials for evaluation of cancer screening.

Authors:  Anthony B Miller
Journal:  World J Surg       Date:  2006-07       Impact factor: 3.352

Review 8.  [Screening from an epidemiologic perspective].

Authors:  N Becker
Journal:  Radiologe       Date:  2008-01       Impact factor: 0.635

9.  The HPV vaccine: an analysis of the FUTURE II study.

Authors:  Michelle Howard; Alice Lytwyn
Journal:  Can Fam Physician       Date:  2007-12       Impact factor: 3.275

10.  Promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A genes in cervical carcinoma.

Authors:  Chiaki Banzai; Koji Nishino; Jinhua Quan; Kosuke Yoshihara; Masayuki Sekine; Tetsuro Yahata; Kenichi Tanaka
Journal:  Int J Clin Oncol       Date:  2013-03-14       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.